主要胃扩散型大B细胞淋巴瘤的Helicobacter pylori根除治疗:一个单中心分析
Makoto Saito1, Akio Mori2, Sayaka Kajikawa2
1Blood Disorders Center, Aiiku Hospital, Sapporo 064-0804, Hokkaido, Japan. ikyoku@aiiku-hp.or.jp.
World journal of clinical cases
|October 30, 2023
概括
Helicobacter pylori (H. pylori) 的根除显示出治疗早期胃扩散性大B细胞淋巴瘤 (DLBCL) 的前景. 在H. pylori治疗后单个病变的患者中观察到完全缓解.
科学领域:
- 胃肠病学 胃肠病学
- 在瘤学瘤学.
- 传染性疾病 传染性疾病
背景情况:
- Helicobacter pylori (H. pylori) 根除对胃扩散性大B细胞淋巴瘤 (DLBCL) 的影响尚不清楚,与其已确定的对MALT淋巴瘤的影响不同.
- 初级胃DLBCL需要进一步调查关于H. pylori根除疗法的情况.
研究的目的:
- 为了确定H. pylori根除治疗初级胃DLBCL的有效性.
- 评估H. pylori根除作为胃DLBCL的治疗选择.
主要方法:
- 对6例胃DLBCL病例 (3例新发,3例先前发病) 的回顾性分析.
- 在这些情况下,评估H. pylori根除治疗的疗效.
主要成果:
- 在H. pylori根除后,所有3名单个胃DLBCL病变的患者都实现了完全缓解 (CR).
- 一位患有单一病变的患者仅通过H. pylori根除,维持了CR超过6年.
- 患有多个胃DLBCL病变的患者没有观察到CR;有些患者获得了部分反应或需要化疗/放射治疗.
结论:
- 根除 H. pylori 是一个潜在的有价值的治疗老年患者单创伤,低负荷的初级胃 DLBCL.
- 建议在选择的胃DLBCL患者中尝试根除H. pylori.
相关概念视频
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
420
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
420
Peptic Ulcer Disease IV: Management
96
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
96
Gastritis III: Clinical Manifestations and Management
292
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
292
Peptic Ulcer Disease V: Surgical Management and Nursing Care
316
Surgical management and nursing care are crucial in treating Peptic Ulcer Disease (PUD). Here is an organized and enhanced overview of the surgical interventions and the associated nursing care for PUD:
Surgical Interventions for Peptic Ulcer Disease
Surgical Interventions for Peptic Ulcer Disease
316
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
138
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
138
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
122
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
122


